13F Pro Quality Score

50.5/100

Rank #1,594 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

21.4/100

Profitability

67.0/100

Balance Sheet

75.9/100

Earnings Quality

62.1/100

Free Cash Flow

47.0/100

Institutional Flow

17.5/100

Revenue Scale

61.6/100

Dilution Risk

76.7/100
Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Unusual Activity in IOSP

Events flagged as statistical outliers against IOSP's own multi-year baseline — not fixed dollar thresholds.

IOSP Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for INNOSPEC INC. (IOSP), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IOSP at 50.5/100 on a 32-signal composite quality model, placing it at rank #1,594 of 2,962 stocks — the bottom half of the AI-ranked universe. IOSP scores in the top quartile across balance sheet strength (75.9). Areas of concern include institutional flow (17.5) and revenue growth (21.4), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), INNOSPEC INC. reports quarterly revenue of $491.4M, net income of $30.8M, an operating margin of 8.1%. Top institutional holders of IOSP by reported 13-F value include BlackRock, Allspring Global Investments, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. IOSP trades on the Nasdaq exchange and files with the SEC under CIK 1054905. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IOSP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for INNOSPEC INC. directly from SEC EDGAR. INNOSPEC INC.'s 13F Pro composite quality score has ranged between 33 and 70 since 2021, currently 50.5 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.

Fun facts about INNOSPEC INC.

Quirks, history, and lore behind IOSP — the kind of stuff that makes a stock memorable.

  • 1
    The Basics
    A specialty chemicals company · mid-cap · listed on Nasdaq · with operational roots in the United Kingdom despite its U.S. listing.
  • 2
    The Numbers
    Annual revenue in the range of $500–700 million — not a giant, but a focused operator with healthy margins for a chemicals business.
  • 3
    The History
    Originally part of Associated Octel, a British chemicals group, it was spun off and rebranded in the early 2000s after shedding its legacy leaded-fuel business.
  • 4
    The Secret
    Its core product line keeps engines running cleaner — fuel additives and performance chemicals that refiners and fuel blenders quietly add before the gas reaches your tank.
  • 5
    The Lore
    The company once paid a significant FCPA settlement with U.S. regulators over bribery, then rebuilt its reputation as a compliance-focused specialty chemicals niche leader.
  • 6
    The Giveaway
    Ticker IOSP, a maker of fuel additives and oilfield chemicals, born from Octel Corp — if you know your obscure Nasdaq specialty chemicals names, this is your moment.
▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$491.4M

Net Income

Q2 2026

$30.8M

Operating Margin

Q2 2026

8.1%

ROIC

Q2 2026

11.8%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-3.7% YoY
$1.78BFY 2025
FY22 $1.96BFY23 $1.95BFY24 $1.85BFY25 $1.78B

Operating Income

-27.2% YoY
$129.5MFY 2025
FY22 $187.3MFY23 $161.6MFY24 $177.9MFY25 $129.5M

EPS (Diluted)

+228.9% YoY
$4.67FY 2025
FY22 $5.32FY23 $5.56FY24 $1.42FY25 $4.67

Total Assets

+5.6% YoY
$1.83BFY 2025
FY22 $1.60BFY23 $1.71BFY24 $1.73BFY25 $1.83B

Total Debt

FY 2025
FY22 FY23 FY24 FY25

Op. Cash Flow

-25.0% YoY
$138.3MFY 2025
FY22 $81.7MFY23 $207.3MFY24 $184.5MFY25 $138.3M

Get alerted when IOSP's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for INNOSPEC INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Top Institutional Holders of IOSP

Companies Similar to IOSP

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

HCSG

HEALTHCARE SERVICES GROUP INC

61
AI score
Similar quality profile · 9 shared holders
ADUS

Addus HomeCare Corp

65
AI score
Similar quality profile · 11 shared holders
CON

Concentra Group Holdings Parent, Inc.

66
AI score
Similar quality profile · 11 shared holders
EHC

Encompass Health Corp

67
AI score
Similar quality profile · 7 shared holders
UHS

UNIVERSAL HEALTH SERVICES INC

66
AI score
Similar quality profile · 9 shared holders
LH

LABCORP HOLDINGS INC.

64
AI score
Similar quality profile · 3 shared holders
GEHC

GE HealthCare Technologies Inc.

57
AI score
Similar quality profile · 5 shared holders
BCPC

BALCHEM CORP

68
AI score
Similar quality profile · 12 shared holders

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

Put IOSP on your watchlist

Track score changes the day INNOSPEC INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is IOSP a good stock to buy?

13F Pro's AI-powered analysis of INNOSPEC INC. (IOSP) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IOSP are available on the IOSP stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. IOSP is classified as a mid company.

Which hedge funds own IOSP?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IOSP. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of INNOSPEC INC.'s investment landscape.